A Preliminary Benefit-Risk Assessment of Lamivudine for the Treatment of Chronic Hepatitis B Virus Infection

Author： Zoulim F.  

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.25, Iss.7, 2002-01, pp. : 497-510

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lamivudine: In Children and Adolescents with Chronic Hepatitis B Virus Infection

By Keam S.J.   Scott L.J.  

Pediatric Drugs, Vol. 4, Iss. 10, 2002-01 ,pp. : 687-694

Adis International

Access to resources Recommend Favorite

Lamivudine is effective in paediatric patients with chronic hepatitis B virus (HBV) infection

By  

Inpharma, Vol. 1, Iss. 1287, 2001-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Lamivudine for the treatment of chronic hepatitis B

By Sokal Etienne  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 3, 2002-03 ,pp. : 329-339

Informa Healthcare

Access to resources Recommend Favorite

Clevudine for the treatment of chronic hepatitis B virus infection

By Hui Chee-Kin   Lau George KK  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 10, 2005-10 ,pp. : 1277-1284

Informa Healthcare

Access to resources Recommend Favorite

Benefit-Risk Assessment of Transdermal Fentanyl for the Treatment of Chronic Pain

By Kornick C.A.   Santiago-Palma J.   Moryl N.   Payne R.   Obbens E.A.M.T.  

Drug Safety, Vol. 26, Iss. 13, 2003-01 ,pp. : 951-973

Adis International

Access to resources Recommend Favorite